Efficacy And Safety Of Low-dose Apatinib Combined With TACE And TACE Alone In The Treatment Of Advanced HCC

Objective: To compare the clinical efficacy and safety of low-dose apatinib combined with TACE and TACE alone in the treatment of advanced HCC.Methods: I.This study was conducted in the interventional ward of the first affiliated hospital of China medical university.From November 2017 to January 2019,100 patients were strictly screened out of all patients with advanced liver cancer admitted to this department,among whom 63 were treated with TACE alone and 37 with apatinib combined with TACE.According to the matching factors of gender,age,child-pugh score,BCLC stage and major tumor diameter,A total of 25 eligible patients were selected and enrolled into groups A and B respectively.There was no significant difference in general data between the groups and the comparability was good.II.We follow up all the patients for 12-15 months.3 months after treatment,we observe the changes of AFP level of two groups.And the objective response rates(ORR)every 3months after treatment were compared between the two groups too.Survival rates was compared at 9 and 12 months,such as the median PFS,adverse events in both groups was also compared.III.SPSS 22.0 statistical software was used for data analysis,in which the counting data were tested by c2,the measurement data were presented as mean and standard deviation((?) ±s)for normal distribution,and the t-test was used.The median PFS was statistically analyzed by K-M method,and the survival rate curve was plotted at the same time.Log-rank test was used to analyze the survival difference.Results: I.There was no statistically significant difference in the general characteristic parameters between two groups(p>0.05).II.After 3 months of treatment,The AFP values in both groups decreased significantly(p<0.05).But the difference of AFP values decreasing between two groups was not statistically significant(p>0.05).3.At 3 and 6months after treatment,the differences between the ORR of two groups was not statistically(p<0.05).But at 9 and 12 months,the ORR differences between two groups were statistical significant(p<0.05).IV.The median PFS was 5.5 months in group A and 9 months in group B.The difference is statistically significant(p=0.01<0.05).V.Statistics of adverse reactions: There was no statistically significant difference in theincidence of fever,abdominal pain,nausea,vomiting and other post-embolization syndrome between the two groups(all p<0.05),while the incidence of hypertension,hand-foot syndrome and other adverse reactions in group B was higher than that in group A statistically(p<0.05).Conclusion: Low-dose apatinib combined with TACE is safe and effective in the treatment of advanced HCC.